Biomea Fusion (NASDAQ:BMEA - Get Free Report) will likely be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect Biomea Fusion to post earnings of ($1.00) per share for the quarter.
Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Biomea Fusion Stock Performance
NASDAQ BMEA traded down $0.14 during trading hours on Tuesday, hitting $1.99. 1,217,485 shares of the company's stock were exchanged, compared to its average volume of 926,303. The firm has a market capitalization of $72.12 million, a P/E ratio of -0.50 and a beta of -0.26. The business's 50 day moving average is $3.28 and its 200-day moving average is $5.96. Biomea Fusion has a 12-month low of $1.97 and a 12-month high of $16.29.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on BMEA shares. Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a report on Monday, March 24th. D. Boral Capital reissued a "buy" rating and set a $16.00 price objective on shares of Biomea Fusion in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Biomea Fusion in a research report on Monday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Biomea Fusion presently has an average rating of "Buy" and a consensus target price of $24.64.
Get Our Latest Research Report on BMEA
Biomea Fusion Company Profile
(
Get Free Report)
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Read More
Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
